中医传统手法治疗肱骨外上髁炎

肱骨外上髁炎俗称网球肘,为临床常见疾病.本病虽不属疑难病症,但中西药物疗效不佳.笔者于1995年1月-2002年6月采用中医传统手法治疗肱骨外上髁炎86例,疗效满意.     

近年来针灸治疗肱骨外上髁炎的进展

目的：本文通过全面检索并筛选总结近年来针灸治疗肱骨外上髁炎的研究近况，为针灸治疗肱骨外上髁炎进一步的临床研究提供思路和依据。方法：综合相关（1996-2004年）文献．筛选出临床常用穴并重点介绍不同治疗方法。结果：针灸在治疗肱骨外上髁炎有很好的疗效。结论：针灸治疗肱骨外上髁炎前景广阔。     

肱骨外上髁炎的高频超声诊断价值

目的探讨高频超声对肱骨外上髁炎的诊断价值. 方法应用高频超声观察30例健康志愿者肱骨外上髁,在此基础上检查78例肱骨外上髁炎患者. 结果高频超声能清晰显示肱骨外上髁、伸肌总腱回声.对于常见的由伸肌总腱损伤及撕裂所致的肱骨外上髁炎高频超声不仅有诊断价值,而且对临床治疗有指导意义,对非手术治疗患者超声还可判断疗效. 结论高频超声可作为肱骨外上髁炎患者有效、实用、无创的影像学检查方法.     

手术松解配合自拟活血舒筋汤内服治疗顽固性肱骨外上髁炎16例

肱骨外上髁炎是以肱骨外上髁疼痛为主症,伸腕及端提、前臂旋前受限的一组证候群,俗称"网球肘",若治疗不及时可形成顽固性肱骨外上髁炎,引起疼痛及功能障碍.我院于1996年1月-2000年12月采用手术松解配合自拟活血舒筋汤内服治疗顽固性肱骨外上髁炎16例,取得满意疗效.     

肱骨外上髁炎局部注射治疗方法的临床探讨

目的 探讨对重症肱骨外上髁炎更有效的局部注射方法.方法 80 例重症肱骨外上髁炎病例经局部封闭注射治疗,效果不满意的患者通过Peppering technique 注射法(Pep 法)或常规封闭注射方法追加治疗,经过12 个月观察临床疗效,通过Nirschl 评分法评估比较不同注射方法的治疗效果.结果 80 例肱骨外上髁炎患者经初期局部封闭治疗,优良率为47.5%;经追加治疗后最终优良率为80.0%.两种追加治疗方法临床效果比较,Pep 法优于常规封闭注射方法(P ＜0.01).对于局部封闭追加治疗效果不满意病例,再次采用Pep 法注射仍能取得较好疗效.结论 肱骨外上髁炎的局部封闭治疗是一种简单有效的治疗方法,而对于难治性肱骨外上髁炎病例,Pep 法追加治疗是一个更有效的临床选择.     

小针刀配合红外线治疗肱骨外上髁炎56例

肱骨外上髁炎为临床常见多发性疾病,俗称网球肘,作者于2001年10月至2006年12月间,应用小针刀配合红外线疗法治疗肱骨外上髁炎56例,疗效较好,现报告如下。     

刺络拔罐治疗肱骨外上髁炎30例临床疗效观察

目的:观察刺络拔罐疗法治疗肱骨外上髁炎的临床疗效。方法:运用刺络拔罐疗法治疗肱骨外上髁炎30例,隔日治疗1次,3次为1个疗程,症状较轻者治疗1个疗程,较重者治疗2个疗程,1²个疗程后观察疗效。结果:30例肱骨外上髁炎患者经12个疗程后观察疗效。结果:30例肱骨外上髁炎患者经1²个疗程治疗后,治愈18例,显效7例,好转1例,无效4例,治愈率60.0%,总有效率86.7%。结论:刺络拔罐疗法治疗肱骨外上髁炎具有良好疗效。     

肱骨外上髁炎的外治疗法现状研究

肱骨外上髁炎是以肘关节外侧疼痛为主要表现的慢性劳损性疾病,初起时症状轻微,此病为骨科门诊常见疾病。现肱骨外上髁炎外治法方法众多,本研究就近5年来肱骨外上髁炎治疗文献进行查阅、总结及归纳,以期对肱骨外上髁炎的临床门诊治疗提供有益借鉴。     

局部封闭治疗肱骨外上髁炎疗效分析

目的探讨肱骨外上髁炎局部封闭治疗的疗效。方法对39例肱骨外上髁炎病例进行局部肌筋膜内注射复方倍他米松注射液(封闭治疗),并结合4周肘部制动治疗。结果采用封闭治疗的39例均取得了满意疗效,优良率为94.9%,复发率为7.7%;与对照组相比差异有统计学意义(P<0.01)。结论局部封闭治疗肱骨外上髁炎可取得较好疗效,为保守治疗肱骨外上髁炎的首选方法。     

体外冲击波联合肱骨外上髁及冈下肌内热针治疗肱骨外上髁炎临床观察

目的:观察和分析体外冲击波(ESW)联合内热针治疗肱骨外上髁炎的临床疗效。方法:纳入符合条件的肱骨外上髁炎患者46例,根据患者选择的治疗方式不同(ESW治疗或联合肱骨外上髁及冈下肌内热针治疗),按随机数字表法分为ESW治疗组和联合治疗组,每组23例。2组患者均给予肱骨外上髁ESW治疗,治疗参数设置为探头直径15 mm,...     

Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma

Genetic defects in the IFN-gamma response pathway cause unique susceptibility to intracellular pathogens, particularly mycobacteria, but are rare and do not explain mycobacterial disease in the majority of affected patients. We postulated that acquired defects in macrophage activation by IFN-gamma may cause a similar immunological phenotype and thus explain the occurrence of disseminated intracellular infections in some patients without identifiable immune deficiency. Macrophage activation in response to IFN-gamma and IFN-gamma production were studied in whole blood and PBMCs of 3 patients with severe, unexplained nontuberculous mycobacterial infection. In all 3 patients, IFN-gamma was undetectable following mitogen stimulation of whole blood, but significant quantities were detectable in the supernatants of PBMCs when stimulated in the absence of the patients' own plasma. The patients' plasma inhibited the ability of IFN-gamma to increase production of TNF-alpha by both autologous and normal donor PBMCs, and recovery of exogenous IFN-gamma from the patients' plasma was greatly reduced. Using affinity chromatography, surface-enhanced laser desorption/ionization mass spectrometry, and sequencing, we isolated an IFN-gamma-neutralizing factor from the patients' plasma and showed it to be an autoantibody against IFN-gamma. The purified anti-IFN-gamma antibody was shown to be functional first in blocking the upregulation of TNF-alpha production in response to endotoxin; second in blocking induction of IFN-gamma-inducible genes (according to results of high-density cDNA microarrays); and third in inhibiting upregulation of HLA class II expression on PBMCs. Acquired defects in the IFN-gamma pathway may explain unusual susceptibility to intracellular pathogens in other patients without underlying, genetically determined immunological defects.     

Immunoglobulin administration to fetuses with anemia due to alloimmunization to D

BACKGROUND: The purpose of this study was to examine fetal tolerance of high-dose intravenous immunoglobulin (IVIG), given directly at the time of intravascular transfusion, and its effects on fetal hemolysis and pregnancy outcome in the setting of alloimmunization to D. STUDY DESIGN AND METHODS: Thirteen consecutive D+ fetuses requiring transfusion for maternal alloimmunization received high-dose IVIG (1.0 g/kg) and red cell transfusions. Twenty-four previous, consecutive fetuses with maternal anti-D served as controls. The schedules for subsequent transfusions were the same in the two groups. RESULTS: High-dose IVIG was well tolerated by all fetuses. In the IVIG group, daily decreases in hematocrit were smaller than those in controls after the second administration of IVIG (mean hematocrit decrease, 0.72 percent/day vs. 1.45 percent/day; p = 0.007). No significant difference was found in the total number of fetal transfusions, the gestational age at delivery, the duration of neonatal intensive care, the number of neonates requiring postnatal transfusion therapy, and perinatal mortality. CONCLUSION: In this small pilot study, direct administration to fetuses of IVIG with red cell transfusions was well tolerated and appeared to have a beneficial effect on fetal hemolysis.